Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»HealthCare»Cariflex to Double its Polyisoprene Latex Capacity at the Paulinia Facility in Brazil
    HealthCare

    Cariflex to Double its Polyisoprene Latex Capacity at the Paulinia Facility in Brazil

    Marie JonesBy Marie JonesJuly 17, 2020No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email
    • Cariflex Board of Directors approved the approximate $50 million capital project in April 2020
    • The new plant is expected to be operational in the first quarter of 2021

    Cariflex200717

    Cariflex PTE. Ltd. (Cariflex) today announced that it will be constructing a new large-scale polyisoprene latex plant at its Paulinia, Brazil, facility to meet the strong market demand from its medical and consumer product customers.

    “Cariflex is excited to be making a sizeable investment in the growth of the polyisoprene latex business. Cariflex polyisoprene latex is a unique synthetic alternative to natural rubber latex for dipped goods and various specialty products. With the current strong demand for medical protective equipment such as surgical gloves, we recognize our customers’ needs to have more material available,” said Philippe Henderson, Cariflex Sales & Marketing leader.

    With Cariflex’s increased production capacity and unmatched global service network, its customers can be assured of secure supplies anywhere in the world. Following the addition of this polyisoprene latex unit, the new resulting capacity in Paulinia, Brazil, combined with the existing capacity in Himeji, Japan, will strengthen Cariflex’s position as the global leader of polyisoprene latex with unmatched quality and supply diversity. Customers will benefit from Cariflex IR0401 latex volumes sourced from four distinct production lines.

    The addition of this new production line is replicating the technology of the current fully utilized unit and will double the polyisoprene latex capacity of the site.

    Daelim Industrial Co., Ltd named Prakash Kolluri as Chief Executive Officer of Cariflex Pte Ltd, for the global business. Sean Kim, Chief Executive Officer for Daelim Industrial Co., Ltd, said, “We are delighted to have appointed Mr. Prakash Kolluri who is a huge asset to the company. We are confident Prakash will move Cariflex Pte Ltd forward and bring a wealth of experience which will be extremely valuable in driving our future growth globally.”

    “Our strategic decision of capacity expansion, in support of organic growth, separates us from competition. Our industry-leading polyisoprene latex capacity acts as a catalyst for our valued customer base to make inroads in new geographies. Cariflex is strategically positioned and has a bright future serving medical and other high-value markets,” Prakash Kolluri, Chief Executive Officer mentioned.

    ABOUT Cariflex

    Cariflex is a global leader of isoprene rubber latex (“IR Latex”) and isoprene rubber (“IR”) for medical end markets and other high-value markets with strong growth drivers. Cariflex produces high value-added synthetic rubbers and latexes used for medical materials such as surgical gloves and rubber stoppers and seals for drug delivery devices. Cariflex is a wholly owned subsidiary of Daelim Industrial Co., Ltd.

    For Press Inquiries
    Sang-woo Ryu, Cariflex: sangwoo.ryu@cariflex.com
    Eric Byun, KorCom Porter Novelli (Daelim Industrial’s PR agency): eric@korcom.com

    Cariflex
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleTraceSafe Appoints Marcin Samiec as Chief Privacy Officer
    Next Article China Unicom launches 5G CPE powered by UNISOC V510

    Related Posts

    Micot Pharma Debuts MT200605 Huntington’s Disease Research in a Poster Presentation at MDS 2026 and Expands Development into Neurodegenerative Diseases

    October 12, 2026

    Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform

    October 9, 2026

    Micot’s XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease

    October 5, 2026
    Add A Comment

    Comments are closed.

    Latest News

    • OMP and Eastman Show Decision Velocity in Practice at Gartner Supply Chain Planning Summit 2026
    • OpenWorld Signs Term Sheet to Finance Solar-Powered, Distributed AI Computing Network Initially Integrated with Residential Battery Storage with Tokenized Financing Program of up to $1 Billion
    • Duiba Reports First Profit for AI Short Drama Unit, with Three Consecutive Months of Triple-Digit Monthly Growth
    • ‘AI + Retail’ Dual-Drive Creates Compound Growth: Huitongda Network (9878.HK) Empowers E-commerce Merchants to Improve Quality and Efficiency with ‘Dabi AI’
    • Doubleview Reports First 2026 Drill Assays from Hat Project; H109 Returns 541.2 Metres of 0.27% CuEq and H113-H114 Add South-West Extension Data
    • OpenWorld (NASDAQ: OPNW) Signs Term Sheet to Finance and Operate a Solar-Powered AI Computing Network Built on Tesla Powerwall Batteries
    • Oritain Launches Supplier Intelligence Report, Revealing a New Era of Supply Chain Collaboration
    • Hong Kong Cinema @ BUSAN 2026 concludes successfully
    • GP Energy Tech, a subsidiary of Gold Peak, showcases Nickel-Zinc battery technology at Hong Kong Electronics Fair
    • Kincora Announces Shares for Debt Settlement
    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.